Mounjaro is stronger than Ozempic by most measurable outcomes. In the SURPASS-2 trial, a head-to-head comparison published in The New England Journal of Medicine, all three doses of tirzepatide (Mounjaro’s active ingredient) outperformed the highest approved dose of semaglutide (Ozempic’s active ingredient) for both blood sugar reduction and weight loss. The difference isn’t small, and it comes down to how each drug works in the body.
How the Two Drugs Compare on Weight Loss
In the SURPASS-2 trial, patients on Mounjaro lost significantly more weight than those on Ozempic over 40 weeks. The 5 mg dose produced an average loss of 7.6 kg (about 17 pounds), the 10 mg dose led to 9.3 kg (about 20 pounds), and the 15 mg dose resulted in 11.2 kg (about 25 pounds). Patients on Ozempic’s 1 mg dose lost 5.7 kg (about 13 pounds). Even the lowest dose of Mounjaro beat Ozempic’s highest dose available at that time.
Longer-term data tells a similar story. At 72 weeks, the weight-loss versions of these drugs (Zepbound for tirzepatide, Wegovy for semaglutide) were compared in obesity populations. Patients on the higher doses of Zepbound lost around 20% of their body weight, compared to about 14% for those on the higher doses of Wegovy. That’s a meaningful gap for someone trying to lose 50 or 100 pounds.
There is a caveat, though. A newer, higher dose of semaglutide (7.2 mg) has shown weight loss of around 21% over 72 weeks, which is close to the 22% seen with the highest dose of Zepbound (15 mg) in its pivotal trial. So the gap narrows considerably at the top end of dosing for both medications.
Blood Sugar Reduction
For people with type 2 diabetes, the A1C results followed the same pattern. In SURPASS-2, the 5 mg, 10 mg, and 15 mg doses of Mounjaro lowered A1C by 2.01, 2.24, and 2.30 percentage points, respectively. Ozempic at 1 mg lowered A1C by 1.86 percentage points. If your starting A1C is 8.5%, that’s the difference between landing around 6.2% versus 6.6%, which can determine whether you still need additional diabetes medications.
Why Mounjaro Works Differently
The core reason Mounjaro outperforms Ozempic is that it hits two targets instead of one. Ozempic activates a single receptor called GLP-1, which slows digestion, reduces appetite, and helps your pancreas release insulin when blood sugar rises. Mounjaro activates that same GLP-1 receptor plus a second one called GIP. Both GLP-1 and GIP are hormones your gut naturally releases after eating, and they work together to regulate blood sugar and energy balance.
Interestingly, Mounjaro doesn’t activate the GLP-1 receptor as powerfully as Ozempic does. Its binding strength at that receptor is about five times weaker than natural GLP-1, and its activation potency is roughly 13-fold lower. But it compensates by triggering the GLP-1 receptor in a slightly different way that causes less receptor burnout over time, meaning the signal stays effective longer. Combined with full-strength GIP activation, this dual approach produces better overall results than hammering the GLP-1 pathway alone.
Side Effects: Roughly Similar
Both medications cause gastrointestinal side effects, primarily nausea, vomiting, and diarrhea. These are the most common reasons people reduce their dose or stop treatment. The side effects tend to be worst during dose increases and often improve after a few weeks at a stable dose.
Comparative analyses have found that Mounjaro tends to have slightly fewer reported side effects overall than GLP-1 drugs like Ozempic, though both are in the same general range. For most people, the experience is similar: a period of adjustment with stomach-related discomfort that gradually settles.
Dosing and How You Take Them
Both drugs are once-weekly injections, but their dose ranges differ considerably. Ozempic starts at 0.25 mg weekly for four weeks, then increases to a maintenance range of 0.5 to 1 mg, with a maximum of 2 mg. Mounjaro starts at 2.5 mg weekly for four weeks, then moves through a maintenance range of 5 to 12.5 mg, up to a maximum of 15 mg. The numbers aren’t directly comparable because the molecules are different, but the escalation approach is the same: start low, increase gradually every four weeks to give your body time to adjust.
Different Brand Names for Different Uses
This is a common point of confusion. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. The active ingredients are the same within each pair, but the FDA approvals, available doses, and insurance coverage differ depending on whether the prescription is for diabetes or obesity. You cannot combine Mounjaro or Zepbound with Ozempic or Wegovy.
Heart Health Benefits
GLP-1 drugs as a class have strong evidence for reducing major cardiovascular events like heart attacks, strokes, and cardiovascular death, regardless of whether someone has diabetes. Semaglutide has the more established track record here, with dedicated cardiovascular outcomes trials confirming these benefits.
Tirzepatide’s cardiovascular data is still catching up. A meta-analysis of its clinical trials found it appears safe for the heart with a trend toward fewer events, but those trials weren’t specifically designed to measure cardiovascular outcomes. One large observational study found that tirzepatide was associated with lower rates of heart attack, stroke, and death compared to GLP-1 drugs in people with type 2 diabetes and existing heart disease. Dedicated cardiovascular trials for tirzepatide are ongoing and will provide more definitive answers.
Which One Is Right for You
If raw potency is the question, the answer is straightforward: Mounjaro produces larger reductions in both weight and blood sugar than Ozempic at their standard doses. The gap closes at the newest, highest doses of semaglutide, but across most commonly prescribed doses, tirzepatide delivers more. That said, “stronger” doesn’t always mean “better for you.” Insurance coverage, cost, availability, how you tolerate side effects, and whether you’re treating diabetes, obesity, or both all factor into which medication makes the most sense. Both drugs represent a significant advance over older options, and switching between them is common when one isn’t producing the desired results or is causing too many side effects.